Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

SpO2 Verification Study - Philips Nasal Alar With Nellcor OxiMax SpO2 Board (453564624031)

14 de julio de 2026 actualizado por: Philips Clinical & Medical Affairs Global
The primary purpose of the clinical investigation is to verify the SpO2 accuracy of the Philips AlarX5 SpO2 sensor with Nellcor OxiMax SpO2 Board.

Descripción general del estudio

Estado

Terminado

Condiciones

Intervención / Tratamiento

Descripción detallada

To verify the SpO2 accuracy of the AlarX5 SpO2 sensor (nasal ala application) with the Nellcor OxiMax pulse oximetry technology during non-motion conditions over the range of 70-100% SaO2, when compared with the reference SaO2 obtained from CO-Oximetry analysis of arterial blood samples.

Tipo de estudio

De observación

Inscripción (Actual)

43

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Colorado
      • Louisville, Colorado, Estados Unidos, 80027
        • Element Materials Technology

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto

Acepta Voluntarios Saludables

Sí

Método de muestreo

Muestra no probabilística

Población de estudio

The study population will include a minimum of 36 to 72 healthy adult volunteers.

Descripción

Inclusion Criteria:

  • Participant must have the ability to understand and provide written informed consent
  • Participant is an adult between 18-50 years of age
  • Participant must be willing and able to comply with study procedures and duration
  • Participant is a non-smoker or who has not smoked within 2 days prior to the study

Exclusion Criteria:

  • Participant is considered as being morbidly obese (defined as BMI >39.5)
  • Compromised circulation (i.e., Raynaud's Syndrome), injury, or physical malformation of fingers, hands, nose, ears or forehead/skull or other sensor sites which would limit the ability to test sites needed for the study. Tattoos (e.g. permanent, Henna) or artificial dyes (e.g. spray tan, artificial tanning lotion) in the optical path which would limit the ability to test sites needed for the study. (Note: Certain malformations may still allow participants to participate if the condition is noted and would not affect the sites utilized.)
  • Females who are pregnant
  • Females who are trying to get pregnant with confirmation of positive urine pregnancy test
  • Participants who have smoked in the last 2 days or participants who have refrained, for at least 48 hours, with COHb levels >3% as assessed with a Masimo Radical 7 (Rainbow)
  • Participants with known respiratory conditions such as: (self-reported)

    • uncontrolled / severe asthma
    • flu
    • pneumonia / bronchitis
    • shortness of breath / respiratory distress
    • unresolved respiratory or lung surgery
    • emphysema, COPD, lung disease
    • recent COVID with hospitalization
  • Participants with self-reported heart or cardiovascular conditions such as: (self-reported, except for blood pressure and ECG review)

    • high blood pressure: systolic >140 mmHg or diastolic >90 mmHg on 3 consecutive readings (reviewed during health screen)
    • have had cardiovascular surgery, except successful minor surgery without clinical symptoms (i.e., PFO, PDA)
    • chest pain (angina)
    • heart rhythms other than a normal sinus rhythm or with respiratory sinus arrhythmia (reviewed during health screen)
    • previous heart attack
    • blocked artery
    • unexplained shortness of breath
    • congestive heart failure (CHF)
    • history of stroke
    • transient ischemic attack
    • carotid artery disease
    • myocardial ischemia
    • myocardial infarction
    • cardiomyopathy
    • implantable active medical device such as pacemaker or automatic defibrillator
  • Participants with self-reported health conditions

    • diabetes
    • uncontrolled thyroid disease
    • kidney disease / chronic renal impairment,
    • history of seizures (except childhood febrile seizures)
    • epilepsy
    • history of unexplained syncope
    • recent history of frequent migraine headaches
    • recent symptomatic head injury (within the last 2 months) with continued symptoms
    • cancer requiring chemotherapy, radiation, or current treatment - Participants with known clotting disorders (self reported)
    • history of bleeding disorders or personal history of prolonged bleeding from injury
    • history of blood clots
    • hemophilia
    • current use of blood thinner: prescription or daily use of aspirin
    • Sickle Cell Trait or Disease - Participants with self-reported dermatological conditions at sensor application sites
    • severe dermatitis
    • hyperkeratosis
    • nail fungus - Participants with severe contact allergies to standard adhesives, latex, silicone or other materials found in pulse oximetry sensors, ECG electrodes, respiration monitor electrodes or other medical sensors (self reported)
  • Participants with severe allergies to iodine (only applicable if iodine is used)
  • Participants with severe allergies to lidocaine (or similar pharmacological agents, e.g. Novocaine)
  • Participants with allergies to ultrasound gel
  • Failure of the Perfusion Index Ulnar/Ulnar+Radial Ratio test (Ratio <0.4)
  • Unwillingness or inability to remove nail polish, nail jewelry, or artificial nails from test digits. Bruised nail bed of test digits.
  • Unwillingness or inability to remove makeup, creams, lotions, sunscreen, or powders from application sites on the nose or ear.
  • Unwillingness or inability to cut/trim fingernail(s) of test digits if determined length will interfere with correct application of the sensor
  • Piercing at application site of the ear or nose sensors that may interfere with correct placement of sensor
  • Participants received colored intravascular dye within the past 48 hours (e.g. Indocyanine green, methylene blue, dyes used in cardiac output monitoring)
  • Surgical hardware in pathway of Device Under Test
  • Other known health conditions should be considered upon disclosure

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
Healthy Volunteers
Participants are healthy, non-smoking (or has refrained from smoking for 2 days) competent adults, ages 18 to 50 years.

The experimental Philips AlarX5 SpO2 sensor will be tested with Nellcor OxiMax pulse oximetry technology. The AlarX5 SpO2 sensor will be connected via an adapter cable to an IntelliVue X3 Patient Monitor integrated with a Nellcor OxiMax SpO2 Board. Within the study, biomedical/health related outcomes as it relates to the healthy volunteers are not evaluated. The data collected will be used to evaluate how accurate the pulse oximeter (DUT) is to the reference.

Devices under test are listed below:

  • Nellcor OxiMax SpO2 Board (453564624031) integrated within Philips IntelliVue X3 Patient Monitor (867030)
  • Philips AlarX5, Experimental SpO2 sensor based on the Nasal Alar design (nasal ala and earlobe placement)
  • Philips M1943NL SpO2 Adapter Cable (3m)

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Measurement and comparison of SpO2 accuracy of the AlarX5 SpO2 sensor (nasal ala application) compared to arterial oxygen saturation.
Periodo de tiempo: Up to 6 weeks
Measurement and comparison of SpO2 accuracy of the AlarX5 SpO2 sensor (nasal ala application) compared to arterial oxygen saturation.
Up to 6 weeks

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Measurement and comparison of SpO2 accuracy of the AlarX5 SpO2 sensor (earlobe placement) during non-motion conditions.
Periodo de tiempo: Up to 6 weeks
Measurement and comparison of SpO2 accuracy of the AlarX5 SpO2 sensor (earlobe placement) during non-motion conditions.
Up to 6 weeks

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Evaluation of the pigmentation bias of the AlarX5 SpO2 sensor (nasal ala and earlobe application).
Periodo de tiempo: Up to 6 weeks
Non-disparate performance for the AlarX5 SpO2 sensor.
Up to 6 weeks

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

28 de mayo de 2026

Finalización primaria (Actual)

29 de junio de 2026

Finalización del estudio (Actual)

29 de junio de 2026

Fechas de registro del estudio

Enviado por primera vez

16 de junio de 2026

Primero enviado que cumplió con los criterios de control de calidad

25 de junio de 2026

Publicado por primera vez (Actual)

2 de julio de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

16 de julio de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

14 de julio de 2026

Última verificación

1 de julio de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • SEF-2025-301123

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Descripción del plan IPD

This is currently under consideration.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

Sí

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir